Skip to search formSkip to main contentSkip to account menu

Recurrent Central Nervous System Neoplasm

Known as: Recurrent Central Nervous System Tumor 
The reemergence of a central nervous system neoplasm after a period of remission.
National Institutes of Health

Related topics

Related topics

4 relations
Central Nervous SystemNeoplastic CellNervous system structureRecurrent disease

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
RONC-13. OUTCOMES OF RE-IRRADIATION IN PEDIATRIC PATIENTS WITH RECURRENT CNS TUMORS
Review
2015
Review
2015
IMCT-01PEMBROLIZUMAB: FIRST EXPERIENCE WITH RECURRENT PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS
Patients with progressive primary brain tumors (PBT) are attracted to promising new treatments, even prior to convincing data… 
2012
2012
PC-01. PHASE I AND PHARMACOKINETIC TRIAL OF PTC299 IN PEDIATRIC PATIENTS WITH REFRACTORY OR RECURRENT CNS TUMORS: A PBTC STUDY
CLIN-PEDIATRICS CLINICAL RESEARCH PC-01. PHASE I AND PHARMACOKINETIC TRIAL OF PTC299 IN PEDIATRIC PATIENTS WITH REFRACTORY OR… 
2010
2010
The role of dose escalation with intracavitary brachytherapy in the treatment of localized CNS malignancies: outcomes and toxicities of a prospective study.
2004
2004
Combination chemotherapy with cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) in children with brain tumors
SummaryThe chemotherapeutic combination of cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) was used to treat… 
2000
2000
High-dose carmustine, thiotepa and etoposide followed by autologous bone marrow rescue for the treatment of high risk central nervous system tumors
Forty-two patients (29 newly diagnosed) with high grade gliomas (n = 37), medulloblastoma (n = 2) or non-biopsied tumors (n = 3… 
1998
1998
High-dose thiotepa and etoposide-based regimens with autologous hematopoietic support for high-risk or recurrent CNS tumors in children and adults
The prognosis in patients with primary brain tumors treated with surgery, radiotherapy and conventional chemotherapy remains poor… 
1997
1997
High-dose cyclophosphamide for poor-prognosis and recurrent pediatric brain tumors: a dose-escalation study.
PURPOSE To determine the maximum-tolerated dose (MTD) of cyclophosphamide (CTX) when administered over 2 consecutive days… 
1995
1995
Dose escalation trial of cyclophosphamide with Sargramostim in the treatment of central nervous system (CNS) neoplasms.
We conducted a dose escalation trial of cyclophosphamide plus Sargramostim in the therapy of patients with newly diagnosed or… 
1988
1988
Late recurrence of primitive neuroectodermal Tumor/Medulloblastoma
The period of risk for recurrence of primitive neuroectodermal tumor/medulloblastoma (PNET/MB) is not clearly defined. With… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)